NCT04273139 - Ibrutinib + Venetoclax in Untreated WM | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

June 6, 2022

Study Completion Date

February 1, 2028

Conditions

Waldenstrom MacroglobulinemiaMYD88 Gene Mutation

Interventions

DRUG

IBRUTINIB

Ibrutinib Cycle 1-24 will be administered at a predetermined dose, once daily for 28 days

DRUG

Venetoclax

Venetoclax Cycle 2-24 will be administered daily for 28 days. Predetermined dosage ramp up schedule during cycle 2.

Trial Locations (2)

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston